-
Important Update: Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label
CureDuchenne is sharing a community letter from Sarepta announcing a strategic company restructuring and pipeline
-
MDA Ambassador Guest Blog: The Joy of Accessible Sailing
Mike Huddleston is 62 years old. He is originally from California and now lives in
-
Capricor plans for deramiocel resubmission after FDA rejection
Capricor Therapeutics will resubmit its application for U.S. Food and Drug Administration (FDA) approval of
-
Finding solace: Why I need July’s slower pace
July is my favorite month. Many people who know me might be surprised by that,
-
FDA indicated to Capricor that it will be unable to approve Deramiocel without additional data
Capricor Therapeutics announced that it has received a Complete Response Letter indicating that the FDA
-
Expedia’s New Initiative is Transforming Accessibility for Short-Term Rentals
Lorraine Woodward, founder and CEO of Becoming rentABLE. Expedia Group is not only opening the
-
Capricor Therapeutics Receives Complete Response Letter Regarding Deramiocel (CAP-1002)
On July 9th, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter
-
Post AAV Gene Therapy Resources
As therapeutic options for Duchenne advance, we are seeing continued development of additional AAV gene
-
Moderate pain reported by a third of muscular dystrophy patients
Nearly one-third of people with muscular dystrophy (MD) experience moderate pain, which varies by the
-
Connecting with Experts via PPMD For You
Need direct support for yourself or your child living with dystrophinopathy? PPMD’s PPMD For You program
